Stage 4 Lung Cancer: Targeted therapy & Immunotherapy. Which to Start?

  • Not all lung cancers are the same type.
  • Not all lung cancers are of same stage.
  • Not all lung cancers are treated with similar treatment.

Targeted therapy

For stage 4 lung adenocarcinoma (subset of NSCLC), further testing of EFGR and EML4-ALK mutation are routinely done in Malaysia.

  • ROS1 rearranged mutation drivers is not routinely done although targetable treatment is available.

Those with detected mutation/ presence of oncogenic driver mutation will benefit from targeted therapies (gefitinib, erlotinib, afatinib, osimertinib, crizotinib, ceritinib, alectinib).

Immunotherapy

Patients without oncogenic mutation (EGFR, ALK) are further tested on the percentage of PD-L1-expression in tumour cells.

Certain patients with positive PD-L1 expression in tumour cells will benefit from immunotherapy treatment (pembrolizumab, nivolumab, atezolizumab, avelumab).

I

img_20180409_124548396463875.png
Immunotherapy; Borghaei H et al., N Engl J Med., 2015

II

img_20180409_1247541810914366.png
Immunotherapy; Herbst et al., Lancet, 2015

The subgroup analysis of the above two large studies’ showed no improvement in overall survival in patients with positive oncogenic mutation driver (EGFR) treated with immunotherapy.

Finally

So, in general practice:

  • Patients with positive oncogenic mutation driver (EGFR, ALK) are treated with targeted therapy.
  • Patients with positive oncogenic mutation driver and positive PD-L1 expression are treated with targeted therapy and immunotherapy in later lines of treatment.
  • Patients with negative oncogenic mutation driver and positive PD-L1 expression are treated with immunotherapy.
  • Patients with negative oncogenic mutation driver AND negative PD-L1 expression are treated with chemotherapy.

Of course, the above are just simplistic view of the ever expanding treatments options available for advanced lung cancer.

Many studies are looking into optimal sequencing or combination of treatments, which could change the above once results are made available.

UPDATE (28/7/2018)

Screen Shot 2018-07-29 at 5.10.06 PM
Immunotherapy ineffective in EGFR-mutated non-small cell lung cancer (Lee, JTO, 2016)

The conclusion from the above study was that in EGFR-mutated non small cell lung cancer (NSCLC), immunotherapy (pembrolizumab, nivolumab and atezolizumab) did not improve survival when compared with palliative chemotherapy (docetaxel) in second-line NSCLC treatment.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s